Symptom control in patients with asthma using inhaled corticosteroids/long-acting β2-agonists (fluticasone furoate/vilanterol or budesonide/formoterol) in the US: a retrospective matched cohort study

被引:3
作者
Averell, Carlyne M. [1 ]
Laliberte, Francois [2 ]
Germain, Guillaume [2 ]
Duh, Mei Sheng [3 ]
Lima, Robson [4 ]
Mahendran, Malena [2 ]
Slade, David J. [5 ]
机构
[1] GlaxoSmithKline Plc, US Value Evidence & Outcomes, Res Triangle Pk, NC USA
[2] Ltee, Grp Anal, Hlth Econ & Outcomes Res, Montreal, PQ, Canada
[3] Anal Grp Inc, Hlth Econ & Outcomes Res, Boston, MA USA
[4] GlaxoSmithKline Plc, US Med Affairs, Res Triangle Pk, NC USA
[5] GlaxoSmithKline Plc, Clin Sci, Res Triangle Pk, NC USA
关键词
Asthma; exacerbations; long-acting beta(2)-agonist; inhaled corticosteroids; fluticasone furoate; vilanterol; asthma control; short-acting beta(2)-agonist; EXACERBATIONS; ADHERENCE; OUTCOMES; RISK;
D O I
10.1080/02770903.2021.1963767
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Objective: Treatment with fluticasone furoate/vilanterol (FF/VI), an inhaled corticosteroid/long-acting beta(2)-agonist therapy, reduces the risk of severe asthma exacerbations and improves lung function and symptom control in patients with asthma. However, real-world data remain limited among asthma patients in the United States (US). Methods: This retrospective cohort study propensity score (PS) matched adult asthma patients initiating once-daily FF/VI 100/25 mcg with patients initiating twice-daily budesonide/formoterol (B/F) 160/4.5 mcg using a US claims database (January 1, 2015-December 31, 2018). Asthma control was measured by the mean number of short-acting beta(2)-agonist (SABA) canisters dispensed per patient-year (PPY) during follow-up. Time to first, and rates of, overall and severe asthma exacerbations were also measured. Results: After PS matching, 18,531 patients receiving FF/VI were matched to 18,531 patients receiving B/F. Mean SABA canisters dispensed PPY was significantly lower for FF/VI users compared with B/F users (FF/VI: 1.47, B/F: 1.64; p < 0.001). FF/VI use resulted in 13% significantly lower risk of having an overall asthma-related exacerbation and 22% lower risk of a severe exacerbation versus B/F use (overall exacerbation hazard ratio [HR] [95% confidence interval (CI)]: 0.87 [0.82-0.92], p < 0.001; severe exacerbation HR [95% CI]: 0.78 [0.63-0.97], p = 0.027). Asthma-related exacerbation rates per 100 patient-days were also significantly lower for the FF/VI group compared with the B/F group (overall: 0.0475 vs. 0.0558, p < 0.001; severe: 0.0026 vs. 0.0033, p = 0.020). Conclusions: In real-world practice, initiation of once-daily FF/VI 100/25 mcg in adults with asthma was associated with lower use of SABA and fewer asthma-related exacerbations, which may indicate better asthma control, when compared with use of twice-daily B/F 160/4.5 mcg.
引用
收藏
页码:1805 / 1818
页数:14
相关论文
共 27 条
  • [1] Medication adherence in patients with asthma using once-daily versus twice-daily ICS/LABAs
    Averell, Carlyne M.
    Stanford, Richard H.
    Laliberte, Francois
    Wu, Jennifer W.
    Germain, Guillaume
    Duh, Mei Sheng
    [J]. JOURNAL OF ASTHMA, 2021, 58 (01) : 102 - 111
  • [2] Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone
    Bateman, Eric D.
    O'Byrne, Paul M.
    Busse, William W.
    Lotvall, Jan
    Bleecker, Eugene R.
    Andersen, Leslie
    Jacques, Loretta
    Frith, Lucy
    Lim, Jessica
    Woodcock, Ashley
    [J]. THORAX, 2014, 69 (04) : 312 - 319
  • [3] The impact of moderate and severe asthma exacerbations on quality of life: a post hoc analysis of randomised controlled trial data
    Briggs, Andrew
    Nasser, Shuaib
    Hammerby, Eva
    Buchs, Sarah
    Virchow, J. Christian
    [J]. JOURNAL OF PATIENT-REPORTED OUTCOMES, 2021, 5 (01)
  • [4] 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group
    Cloutier, Michelle M.
    Baptist, Alan P.
    Blake, Kathryn V.
    Brooks, Edward G.
    Bryant-Stephens, Tyra
    DiMango, Emily
    Dixon, Anne E.
    Elward, Kurtis S.
    Hartert, Tina
    Krishnan, Jerry A.
    Lemanske, Robert F., Jr.
    Ouellette, Daniel R.
    Pace, Wilson D.
    Schatz, Michael
    Skolnik, Neil S.
    Stout, James W.
    Teach, Stephen J.
    Umscheid, Craig A.
    Walsh, Colin G.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 146 (06) : 1217 - 1270
  • [5] Association between adherence with fixed dose combination fluticasone propionate/salmeterol on asthma outcomes and costs
    Delea, Thomas E.
    Stanford, Richard H.
    Hagiwara, May
    Stempel, David A.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (12) : 3435 - 3442
  • [6] Medication adherence and the risk of severe asthma exacerbations: a systematic review
    Engelkes, Marjolein
    Janssens, Hettie M.
    de Jongste, Johan C.
    Sturkenboom, Miriam C. J. M.
    Verhamme, Katia M. C.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2015, 45 (02) : 396 - 407
  • [7] Barriers and Strategies in Guideline Implementation-A Scoping Review
    Fischer, Florian
    Lange, Kerstin
    Klose, Kristina
    Greiner, Wolfgang
    Kraemer, Alexander
    [J]. HEALTHCARE, 2016, 4 (03)
  • [8] Asthma exacerbations and worsenings in patients aged 1-75 years with add-on tiotropium treatment
    FitzGerald, J. Mark
    Hamelmann, Eckard
    Kerstjens, Huib A. M.
    Buhl, Roland
    [J]. NPJ PRIMARY CARE RESPIRATORY MEDICINE, 2020, 30 (01)
  • [9] Asthma outcomes: Exacerbations
    Fuhlbrigge, Anne
    Peden, David
    Apter, Andrea J.
    Boushey, Homer A.
    Camargo, Carlos A., Jr.
    Gern, James
    Heymann, Peter W.
    Martinez, Fernando D.
    Mauger, David
    Teague, William G.
    Blaisdell, Carol
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2012, 129 (03) : S34 - S48
  • [10] GlaxoSmithKline, 2019, HIGHL PRESCR INF BRE